ANNOUNCEMENT OF APPLICATION FOR ADMISSION TO THE AQUIS GROWTH MARKET

APPLICANT NAME:

Blackpoint Biotech plc

APPLICANT REGISTERED OFFICE, PRINCIPLE PLACE OF BUSINESS (IF DIFFERENT) AND TELEPHONE NUMBER:

48-49 Chancery Lane, C/O Keystone Law, London, England, WC2A 1JF
+44 208 050 6458

DIRECTORS AND PROPOSED DIRECTORS (IF APPLICABLE):

- Michael William Balfour, Non-Executive Chairman
- David Manuel Martinez, Chief Executive Officer
- Alexander James Robert Stormont Wakeford, Chief Financial Officer
- Dr Michael Barry Mayne, Chief Product Officer

APPLICANT SECTOR:

Healthcare

DESCRIPTION OF THE APPLICANT AND ITS ACTIVITIES:

Blackpoint Biotech PLC is a medical cannabinoids company established to fulfil gaps in the medical cannabis market by creating products that provide fast onset of action and accurate dosing.

NAME OF AQSE CORPORATE ADVISER:

First Sentinel Corporate Finance Limited

NUMBER, CLASS AND PAR VALUE OF SECURITIES TO BE ADMITTED:

12,187,179 Ordinary Shares of £0.005 each

SECURITIES IN PUBLIC HANDS AS A PERCENTAGE OF THE TOTAL NUMBER OF SECURITIES IN ISSUE (excluding securities held in treasury):

15.12%

SHAREHOLDERS HOLDING MORE THAN FIVE PER CENT OF THE APPLICANT'S SHARE CAPITAL OR VOTING RIGHTS PRE- AND POST-ADMISSION:

Shareholder	Shares Pre-admission	% Pre-admission	Shares Post-admission	% Post-admission
David Martinez	4,078,102	33.46%	4,078,102	33.46%
Alexander Wakeford	1,581,696	12.98%	1,581,696	12.98%
Michael Mayne	2,105,000	17.27%	2,105,000	17.27%
Creedy Carver Chickens Limited	2,271,410	18.64%	2,271,410	18.64%

TIMETABLE FOR ANY OFFER OF TRANSFERABLE SECURITIES TO THE PUBLIC:

N/A

THE EXPECTED ADMISSION DATE:

TBD

The company has applied to Euroclear to have the shares enabled in CREST and the process has not yet been concluded.

WEBSITE ADDRESS WHERE INVESTOR INFORMATION WILL BE AVAILABLE FOR INSPECTION:

www.blackpointbiotech.com

In respect of an update to a prior application announcement, the date of the original announcement should also be disclosed as follows:

UPDATE TO A PRIOR APPLICATION ANNOUNCEMENT RELEASED ON:

06 July 2023